HIV-1 reverse transcriptase inhibitors have long been central to antiretroviral therapy, effectively impeding the enzyme responsible for converting viral RNA into DNA – a pivotal step in HIV ...

Merck, known as MSD outside the United States and Canada, has announced the presentation of results from the DRIVE-AHEAD study, the second of two pivotal phase 3 clinical trials evaluating the ...

Please provide your email address to receive an email when new articles are posted on . A combination of doravirine (DOR) and islatravir (ISL) was noninferior to current suppressive therapies among ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome for drug development, today announced a new publication in The Proceedings of the ...

On the third day of the J.P. Morgan Healthcare Conference, Arbor Biotechnologies and Vertex Pharmaceuticals announced that they would be expanding into reverse transcription-based in vivo genetic ...